Jb Chemicals & Pharmaceuticals Ltd. · NSE:JBCHEPHARM
Jb Chemicals & Pharmaceuticals — Q4 FY21 Earnings Presentation
20 slides from Jb Chemicals & Pharmaceuticals's earnings presentation, Jun 14, 2021
Slide 1: J. B. Chemicals & Pharmaceuticals Limited
J. B. CHEMICALS & PHARMACEUTICALS LIMITED June 14, 2021 National Stock Exchange of India Ltd. Exchange Plaza, C-1, Block-G, Bandra Kurla Complex Bandra (E) Mumbai 400 051 Scrip Code : JBCHEPHARM Dear Sir, Sub: Company Presentation Enclosed is Company's presentation on financial results for the quart
Slide 2: Q4 & FY21 – Financial Results
Q4 & FY21 – FINANCIAL RESULTS JB CHEMICALS AND PHARMACEUTICALS LIMITED
Slide 3: Disclaimer
Disclaimer The picture can't be display ed. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in a
Slide 4: Index
Index 4 8 14 Company Overview Q4 & FY21 Financial Historical Financial Performance Performance 3
Slide 5: Company Overview
“ey Company Overview
Slide 6: Corporate Snapshot
Corporate Snapshot India field force Years of operations with Brands among top 300 Growth in chronic 40+ 5 21% #2,100+ expanded, significantly consistent track record brands, contributing therapies* in the over FY17-FY20 with across multiple over 70% of domestic domestic formulations therapy-focused
Slide 7: Domestic Formulations: Outperformance Driven by Strong Brands
Domestic Formulations: Outperformance Driven by Strong Brands Strong performance in chronic therapies JBCPL is the among the fastest Leadership position Chronic Therapies (%) Domestic Formulations* (INR cr) growing pharma companies in the covered markets 892 CAGR: 15% 797 675 21% 35% 588 Vs market g
Slide 8: International Business: Clearly Defined Businesses Across Geographies
International Business: Clearly Defined Businesses Across Geographies International Formulations CMO Direct presence in Russia Distributor relationships in the Leading global position in $4.6 bn Marquee global clients in and South Africa US, Asia, Africa and LatAm lozenges market opportunity pharma
Slide 9: Q4 & FY21 Financial Performance
Q4 & FY21 Financial Performance 8
Slide 10: CEO’s Message
CEO’s Message Nikhil Chopra, CEO, JBCPL on Business Outlook: “Our financial performance for FY21 has been encouraging in one of the most challenging periods in recent history. We are pleased with the strength showcased by all our business units – with the India business continuing to record market-b
Slide 11: Financial Overview
Financial Overview Revenues (INR cr) o Robust performance with strong revenue growth momentum during the 15% year for both, the Domestic formulation and the international business. 2,043 1,775 o Domestic Formulations maintains secular outperformance compared to IPM growth rates, driven by strength
Slide 12: Financial Overview
Financial Overview Profit Before Tax (INR cr) 597 71% 349 97% o Strong operating performance and subdued expenses base due to COVID- 132 67 19 lockdown, also had a positive impact on the PBT for the year. o Certain non recurring income related to sale of product registration ( ~Rs. Q4 FY20 Q4 FY
Slide 13: Revenue Analysis
Revenue Analysis o India business delivered a robust market beating performance through the year: Domestic Formulations* (INR cr) JBCPL at 21% growth vs IPM market at 4.5% (IQVIA MAT 21 data) • Improved overall rank by four positions in IPM from #32 to #28 12% 892 • Business driven by growth in ou
Slide 14: Q4 & FY21 – Financial Performance
Q4 & FY21 – Financial Performance Particulars (Rs. Crore) Q4 FY21 Q4 FY20 YoY Growth FY21 FY20 YoY Growth Revenue from Operations 528.5 443.5 19% 2,042.5 1,774.7 15% Cost of Goods Sold 194.5 147 32% 701.5 630.8 11% Employee Benefit Expenses 86.2 85.5 0.8% 340.6 322.9 5.5% Other Expenses 123.9 119.3
Slide 15: Historical Financial Performance
Historical Financial Performance 14
Slide 16: Strong revenue growth
Strong revenue growth Domestic Formulations* (INR cr) Revenues (INR cr) International Business** (INR cr) CAGR:15% CAGR:13% 2,043 CAGR: 11% 892 1,775 1,127 797 1,643 942 954 675 1,413 816 588 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 EBITDA (INR cr) Profit After Tax (INR cr) Earnin
Slide 17: Financial Performance Analysis
Financial Performance Analysis Particulars FY18 FY19 FY20 FY21 Gross Margin 61.9% 63.7% 64.5% 65.7% Employee Cost/Revenues 17.8% 17.5% 18.2% 16.7% Operating Expenses/Revenues 28.8% 27.5% 25.0% 21.5% EBITDA Margin 15.4% 18.6% 21.3% 27.4% EBIT Margin 11.3% 15.2% 17.5% 24.1% Net Margin 10.0% 11.8% 15.3
Slide 18: Substantial improvements in shareholder returns and consistent cash generation
Substantial improvements in shareholder returns and consistent cash generation ROE (%) ROCE (%) Net Cash Position (INR cr) 663 42% 424 455 29% 392 24% 15% 25% 19% 13% 10% FY18 FY19 FY20 FY21 FY18 FY19 FY20 FY21 Working Capital (INR cr) Working Capital (# days) Operating Cash Flow (INR cr) Free Cash
Slide 19: About J.B. Chemicals & Pharmaceuticals Limited
About J.B. Chemicals & Pharmaceuticals Limited J.B. Chemicals and Pharmaceuticals Limited (JBCPL) (BSE: 506943 | NSE: For further information, please JBCHEPHARM | ISIN: INE572A01028), established in 1976, is one of the fastest growing pharmaceutical companies in India and a leading player in the hyp
Slide 20: Thank You
Thank You 19
J. B. Chemicals & Pharmaceuticals — Q4 FY21 Earnings Presentation on 6ix